SY vs TLSI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
SY presents a contradictory profile: a stable Piotroski F-Score of 5/9 and strong liquidity, contrasted by a catastrophic earnings track record. While the company maintains a very low Price-to-Sales ratio (0.19) and healthy revenue growth (24.8% YoY), it has failed to beat earnings estimates in the last four quarters with massive negative surprises. The technical trend is completely bearish (0/100), and the shift from profitability in 2024 back to significant losses in 2025-2026 suggests a failing operational turnaround.
TLSI exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -6.79, indicating negative shareholders' equity. While the company shows strong top-line revenue growth of 59.80% and high gross margins, these are offset by a devastating profit margin of -86.88% and consistent earnings misses. The stark disconnect between the 'Strong Buy' analyst consensus and the bearish insider selling by the CEO and officers suggests a high-risk speculative profile. Overall, the deterministic health indicators signal a high probability of further capital erosion or dilution.
Compare Another Pair
Related Comparisons
SY vs TLSI: Head-to-Head Comparison
This page compares So-Young International Inc. (SY) and TriSalus Life Sciences, Inc. (TLSI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.